KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Exchange Rate Effect (2019 - 2025)

Ionis Pharmaceuticals has reported Exchange Rate Effect over the past 7 years, most recently at -$43000.0 for Q4 2025.

  • Quarterly results put Exchange Rate Effect at -$43000.0 for Q4 2025, up 91.15% from a year ago — trailing twelve months through Dec 2025 was $702000.0 (up 357.14% YoY), and the annual figure for FY2025 was $702000.0, up 357.14%.
  • Exchange Rate Effect for Q4 2025 was -$43000.0 at Ionis Pharmaceuticals, up from -$82000.0 in the prior quarter.
  • Over the last five years, Exchange Rate Effect for IONS hit a ceiling of $595000.0 in Q2 2025 and a floor of -$486000.0 in Q4 2024.
  • Median Exchange Rate Effect over the past 5 years was -$33000.0 (2024), compared with a mean of $12600.0.
  • Biggest five-year swings in Exchange Rate Effect: crashed 1800.0% in 2022 and later soared 2686.96% in 2025.
  • Ionis Pharmaceuticals' Exchange Rate Effect stood at -$68000.0 in 2021, then surged by 902.94% to $546000.0 in 2022, then plummeted by 39.56% to $330000.0 in 2023, then plummeted by 247.27% to -$486000.0 in 2024, then skyrocketed by 91.15% to -$43000.0 in 2025.
  • The last three reported values for Exchange Rate Effect were -$43000.0 (Q4 2025), -$82000.0 (Q3 2025), and $595000.0 (Q2 2025) per Business Quant data.